The U.S. Food and Drug Administration (FDA) has set a target - TopicsExpress

The U.S. Food and Drug Administration (FDA) has set a target review date of July 5, 2015, for the combination therapy of lumacaftor and ivacaftor to treat people with cystic fibrosis ages 12 and older who have two copies of the F508del mutation. The FDA granted a request by Vertex Pharmaceuticals Inc., the developer of the drug, for an accelerated review of the combination therapy application. The potential combination therapy is the first to target the underlying cause of CF in people with two copies of the F508del mutation, the most common form of the disease.

Quarcite statue of Osorkon From Karnak, Egypt 22nd Dynasty,

I cannot even call them to tell them. VERIZON SUCKS ---As i

IITs, Google & Nasscom launch Job Ready online courses IITs

News Release for Monday, 7/14/14: On 7/08/14 at 6:00 a.m.,

Provoking One Another There was a wealthy Christian banker who

Have you ever wonder what it feels like to see the world in

Throw it away... I think about the life I live A figure made

Tu vois je suis cette fille quon ne remarque par forcement , celle

[Profesional Breakdancer Workout] Everyone knows that being a

Who Wants To Gain Followers In Just A Minute? and autoliker 1,000

God does not speak in secret Isaiah 45:19 - I have not spoken

Aki tudja, hllgassa meg a Lánchíd rádió Kulissza c. műsorát.

Preparing for Wednesdays workshop. #art #workshop This class is a

An older message from a fellow facebooker from awhile

What does a covenant of peace mean? What does it entitle a

Why I’m against Obasanjo —Kashamu

Positivity is the greatest asset in any situation. In

DISCLAIMER: THIS ARE NOT MY WORDS!! Senator, Hassan Omar, who is

It appears that ppl have to be a hell of a lot more aware of

What are you having for Breakfast? Here are some healthy ideas and

Dailymotion KPOO Radio

Best Web Photo Gallery